Our lab aims to reverse glial scar back to normal neural tissue by gene delivery and/or chemical treatment.
Recently, We have discovered a cocktail of small molecules that can reprogram human brain astroglial cells into neuron-like cells after eight-to-ten days of chemical treatment.The small molecule induced neurons could survive for more than five months in cell culture, where they formed functional synaptic networks. When injected in the brains of living mice,the reprogrammed human neurons were integrated into the neural circuits and survived there for at least one month.
The new technology opens the door to the future development of drugs that patients with brain disorders could take as pills to regenerate neurons!
Learn more: Chemically transform human glial cells into neurons for brain repair
The Latest on: Gene delivery
[google_news title=”” keyword=”gene delivery” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]
via Google News
The Latest on: Gene delivery
- Regeneron, Mammoth Biosciences collaborate to pursue next-generation CRISPR-based gene editing for multiple diseaseson April 26, 2024 at 8:30 pm
Regeneron, Mammoth Biosciences collaborate to pursue next-generation CRISPR-based gene editing for multiple diseases: Tarrytown, New York Saturday, April 27, 2024, 09:00 Hrs [IST] ...
- Are Ghosts Promos Too Spoilery? Did Gene Simmons Rock Idol? Did Conners Tease Lottery Redo? Can Outlander Heat Be Repeated? And More Qs!on April 26, 2024 at 8:43 am
We’ve got questions, and you’ve (maybe) got answers! With another week of TV gone by, we’re lobbing queries left and right about lotsa shows including Ghosts, Outlander, American Idol and NCIS! 1 | ...
- Scientists learn from caterpillars how to create self-assembling capsules for drug deliveryon April 26, 2024 at 8:00 am
Self-assembling molecules that spontaneously organize themselves to form complex structures are common in nature. For example, the tough outer layer of insects, called the cuticle, is rich in proteins ...
- U.S. FDA Approves Pfizer’s BEQVEZ™ (fidanacogene elaparvovec-dzkt), a One-Time Gene Therapy for Adults with Hemophilia Bon April 26, 2024 at 7:45 am
Pfizer Inc. (NYSE: PFE) announced today that the U.S. Food and Drug Administration (FDA) has approved BEQVEZ™ (fidanacogene elaparvovec-dzkt) for the ...
- FDA Approves Second Gene Therapy for Hemophilia Bon April 26, 2024 at 7:38 am
Pfizer reported a list price of $3.5 million for its new gene therapy, Beqvez, for adults with this rare bleeding disorder.
- Regeneron Pays Mammoth $100M to Access CRISPR Enzymes for AAV Deliveryon April 25, 2024 at 8:18 am
Regeneron will use Mammoth Biosciences’ tiny Cas enzymes to deliver in vivo CRISPR-based gene editing therapies to tissues and cell types beyond the liver, the companies announced Thursday.
- Regeneron, Mammoth Launch In Vivo CRISPR Gene Editing Collaborationon April 25, 2024 at 8:00 am
Regeneron Pharmaceuticals will use Mammoth Biosciences’ CRISPR-based ultracompact gene editing platform to develop in vivo therapies for tissues and cell types beyond the liver.
- Regeneron to collaborate on gene editing therapies with Doudna-founded Mammothon April 25, 2024 at 7:10 am
Regeneron Pharmaceuticals and Mammoth Biosciences will collaborate to research, develop and commercialize gene editing therapies for multiple diseases, the companies said on Thursday.
- Regeneron signs Mammoth gene editing deal worth $100M upfronton April 25, 2024 at 1:49 am
Mammoth’s ultracompact nucleases and associated gene editing systems will complement the delivery mechanism. “After years spent developing our next-generation delivery approaches, we are eager to ...
via Bing News